NimoVent

NimoVent is a proprietary microparticle formulation of the FDA-approved drug nimodipine encapsulated in biodegradable polymers.  NimoVent is designed to reduce ischemic deficits and improve outcomes in patients suffering SAH who undergo endovascular coiling.  Unlike NimoGel, NimoVent will be delivered minimally invasively in the intensive care unit after the patient has undergone endovascular coiling.  The NimoVent will be delivered through an existing intraventricular catheter, so there is no additional procedure required.